Real-world sustained minimal residual disease (MRD) negativity using NGS in multiple myeloma

When Complete Remission is Incomplete

Clinical Actionability of Measurable Residual Disease (MRD) Assessment in the Management of Patients with Hematologic Malignancies: A Case-Based Monograph

The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements

Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma

Real-World Minimal Residual Disease (MRD) Assessment and Trends Using clonoSEQ in B-Cell Acute Lymphoblastic Leukemia and Multiple Myeloma.

Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma